MedTrace Logo

DaZhu Rhodiola Rosea Capsule for Coronary Artery Disease With Angina Pectoris

NCT03633890 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2018-08-16

No results posted yet for this study

Summary

This study aims to evaluate the efficacy and safety of traditional Chinese medicine DaZhu Rhodiola Rosea Capsule for treatment of coronary artery disease by observing angina symptoms, exercise capacity, and quality of life.

Conditions

Interventions

DRUG

DaZhu Rhodiola Rosea Capsule

Oral administration, 4 capsules, 3 times a day, for 8 weeks

DRUG

DaZhu Rhodiola Rosea Simulation Capsule

Oral administration, 4 capsules, 3 times a day, for 8 weeks

Sponsors & Collaborators

  • Jiangsu Kangyuan Pharmaceutical Co. Ltd

    collaborator UNKNOWN

  • Beijing Anzhen Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-31
Primary Completion
2019-02-28
Completion
2019-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03633890 on ClinicalTrials.gov